This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an investment analysis.

Former institutional trader Kevin Muir flags caution on chasing this market as he sees some big market whales nearing the end of a U.S. stock buying spree.

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...

Trump Cuts Tariff Rate to 15% on Japan - The U.S. and Japan struck a major trade deal overnight. Trump confirmed a 15% tariff ...